LON:NIOX - Niox Group PLC
Executive Summary
Niox Group PLC (LON:NIOX) is a UK-listed medical device company specialising in point-of-care diagnostics for asthma and respiratory conditions, with its core franchise built around fractional exhaled nitric oxide (FeNO) testing. The group markets the NIOX VERO device and a recurring consumables stream (single-use sensors and breathing handles) to clinicians, hospitals and respiratory specialists worldwide, holding a leading position in the niche FeNO category. It reports in GBX on the London Stock Exchange and operates within the Healthcare - Medical Devices segment.
The investment case rests on continued double-digit revenue and EBITDA growth, sustained clinical adoption of FeNO testing, and an uplift in research-use revenue as respiratory trial activity normalises. The principal near-term catalyst is the 2025 final results and any accompanying trading commentary, followed by the 21 May 2026 Annual General Meeting at which shareholders will vote on the 2025 final dividend. The primary risk is product concentration: FeNO-related sales dominate the mix and any softening in asthma-testing volumes, or competitive pressure, would weigh disproportionately on group earnings.
OPPORTUNISTIC BUY. Conviction Score: 59/100. The thesis would be upgraded on evidence of meaningful new product, geographic or end-market diversification, or a hard catalyst such as a major contract win or strategic licensing deal; it would be downgraded on a clear deceleration in FeNO revenue growth, margin compression, or the emergence of a credible low-cost competitor.
Business Model
Niox generates revenue principally through the sale of its NIOX VERO point-of-care FeNO analysers and, more importantly, the associated single-use consumables - disposable breathing handles and sensors - required for every test. The hardware footprint drives an installed base, and the consumables stream produces the recurring revenue characteristic of a razor-and-blade model. Revenue is split between Clinical (asthma diagnosis and management) and Research use, with Research-use revenue showing particular momentum as respiratory and pharmaceutical trial activity recovers.
Customers include hospital respiratory departments, specialist pulmonology clinics, primary-care physicians and pharmaceutical / academic research institutions running asthma and inflammatory-airway studies. Pricing is set per-test via the consumable, giving the model natural leverage as testing volumes rise in line with guideline-driven adoption of FeNO measurement. Reported FY 2024 group revenue grew at a double-digit pace, with adjusted EBITDA up 21% to GBP 16.7 million (from GBP 13.8 million), reflecting operating leverage on the recurring consumables base.
The competitive moat is narrow but real: NIOX is the established brand in FeNO with a deep installed base, regulatory clearances across major markets, and clinical-evidence backing that has taken years to build. The constraint, highlighted in the company's own SEC-filed risk disclosures, is concentration - a single product platform accounts for the bulk of group revenue, so durability of the thesis is tied to continued FeNO adoption rather than diversification.
Financial Snapshot
Recent Catalysts
[March 2026] - Niox Group published quarterly earnings results showing GBX 4.03 earnings per share for the quarter and a 14.37% net margin, with the release carried via Digital Look and secondary outlets. Source: Digital Look via Markets Daily.
[24 March 2026] - Niox Group reported earnings results confirming GBX 4.03 EPS for the quarter and a return on equity referenced in the release. Source: Markets Daily earnings coverage.
[17 April 2026] - Insider Jonathan Emms sold 325,273 shares, disclosed via company filings and reported by financial news outlets. Source: Daily Political coverage of insider disclosure.
[2026 AGM notice] - Niox Group published the notice of its 2026 Annual General Meeting, confirming logistical details and the availability of the 2025 annual report to shareholders. Source: Investegate RNS announcement.
[21 May 2026] - The 2026 Annual General Meeting is scheduled, at which shareholders will vote on the 2025 final dividend and other resolutions. Source: Niox Group RNS announcement via TipRanks / Investegate.
[1 May 2026] - Niox Group disclosed Total Voting Rights in accordance with the FCA's Disclosure and Transparency Rules. Source: ADVFN regulatory news feed.
Thesis Evaluation
Bull Case (25% weight)
FeNO testing continues its guideline-driven adoption curve, research-use revenue accelerates as pharmaceutical trial pipelines fill, and operating leverage compounds on the consumables base, allowing adjusted EBITDA to expand materially above FY 2024's GBP 16.7 million. Under this scenario the shares re-rate towards the upper end of the 52-week range and beyond. Bull case 12-month price target: 85p.
Base Case (50% weight)
Revenue grows at a steady double-digit pace supported by both Clinical and Research channels, with margins broadly stable around recent levels, and the stock trades on a re-rating consistent with sustained mid-teens earnings growth. Base case 12-month price target: 72p.
Bear Case (25% weight)
FeNO product concentration bites: clinical testing volumes soften, research-use revenue normalises off recent highs, and a credible low-cost alternative enters key markets, compressing both revenue growth and margins. The shares derate towards the 52-week low of 53.84p. Bear case 12-month price target: 48p.
Key Risks
- Product concentration in FeNO: The bulk of group revenue derives from a single FeNO platform, leaving the model exposed to any disruption in asthma-testing demand or clinical guidelines. Estimated probability: 35%. Impact: severe.
- Competitive entry in FeNO: A credible low-cost competitor or alternative biomarker entering major markets could erode pricing power on both devices and consumables. Estimated probability: 20%. Impact: severe.
- Insider selling: Disclosed share sales by insiders, including the April 2026 sale by Jonathan Emms, can signal weaker conviction from those closest to the business and pressure sentiment. Estimated probability: 60%. Impact: low.
- Currency translation: With significant US dollar and euro revenue streams, reported earnings are sensitive to GBP appreciation against these currencies. Estimated probability: 40%. Impact: moderate.
- Regulatory and reimbursement risk: Changes to clinical guidelines, reimbursement coverage or regulatory clearances in core markets could materially affect demand for FeNO testing. Estimated probability: 25%. Impact: moderate.
- Lack of hard catalysts: The investment case relies on soft earnings momentum rather than disclosed contract wins, M&A or licensing deals, leaving the stock vulnerable to negative drift in the absence of positive news flow. Estimated probability: 50%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: Long-term, risk-tolerant investors with a minimum holding period of 12 - 18 months who are comfortable with single-product-platform concentration risk in the medical-devices space and who want exposure to a cash-generative, recurring-revenue respiratory diagnostics franchise trading well below its 52-week high. A tolerance for short-term price volatility and the absence of immediate hard catalysts is required, given that the thesis is constructed around operating momentum rather than near-term event-driven upside.
Avoid if: Investors require diversified revenue streams, hard near-term catalysts such as contract wins or M&A, or stable, low-volatility cash flows. Those with a low tolerance for insider selling signals, single-product concentration, or healthcare-policy / reimbursement risk should also steer clear, as should investors with a holding-period horizon shorter than 12 months who may be forced to sell before the operating-leverage thesis plays out.
Recommendation
OPPORTUNISTIC BUY - 59/100. The tier reflects a constructive operating story with double-digit revenue and EBITDA growth, recurring consumables economics, and a re-rating opportunity from a price materially below the 52-week high of 77.6p, but it is held back by product concentration, the absence of hard catalysts in the public news flow, and recent insider selling that caps near-term sentiment. The call would be upgraded on a credible diversification move, a disclosed contract win or strategic partnership, or a sustained acceleration in research-use revenue. It would be downgraded on clear deceleration in FeNO clinical volumes, margin compression, evidence of competitive entry, or further insider disposals of meaningful size. At the current price of 60.40p the shares trade above our buy ceiling of 56.00p: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is 69.25p, 15% above the current price of 60.40p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below 56.00p - below this level the upside to the base-case target (72.00p) is at least 2x the downside to the bear case (48.00p), the minimum risk/reward we require before committing new capital.
between 56.00p and 72.00p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above 72.00p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if A sustained deceleration in FeNO clinical and research revenue to single-digit growth, margin compression below recent levels, or the loss of a major regulatory clearance or reimbursement status in a core market, regardless of price - the bear target of 48.00p is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 54 |
| 2026-06-28 | 59 |
| 2026-05-30 | 59 |
| 2026-04-27 | 59 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow covering company earnings releases, regulatory announcements via RNS / Investegate, insider transaction disclosures, AGM and dividend timetable notices, and third-party financial-news commentary on share-price action and results.
Primary source types: Regulatory filings and RNS announcements (Investegate, ADVFN), company press releases and investor relations materials (investors.niox.com), earnings results and trading updates issued by the company, and publicly available financial-news coverage of those disclosures.
Key sources
- INTERIM RESULTS | Company Announcement | Investegate
- Final Results, 01 April 2025 07:00 | RNS News | NIOX - NIOX GROUP PLC | Investor Meet Company
- NIOX Stock Forecast - Niox Group PLC
- Niox Group PLC (NIOX:LSE) Share price, analysis, charts ...
- Press releases - NIOX?
- NIOX Group plc (NIOX) Competitive Analysis & Comparison (2026)
- NIOX Group 2026 Company Profile
- Niox Group Stock Price Forecast. Should You Buy NIOX.L?
- MSN Money
- Niox Group share price | NIOX | Brokers view
Data correct as of 2026-08-01.